anti-SialylTn mAbs (Siamab Therapeutics)

N/A

Report date: 2025/06/11 10:19:51

Base Information

Drug Nameanti-SialylTn mAbs (Siamab Therapeutics)
Drug Alias NameST1 program (Siamab)anti-TACA1 mAbs (Siamab Therapeutics)humanized anti-SialylTn mAbs (Siamab Therapeutics)SIA-103SIA-01 +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionSialyl Thomsen nouveau antigen inhibitors
TargetsUpdating
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSiamab Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSiamab Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A